Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CONMED (CNMD)

CONMED stockholders approve 2025 Long-Term Incentive Plan, elect eight directors

Neutral Impact 2 of 5 shareholder Written later

At its annual meeting on May 20, 2025, CONMED stockholders approved the 2025 Long-Term Incentive Plan, elected eight directors, approved the advisory vote on executive pay, and ratified PricewaterhouseCoopers LLP as auditor for fiscal 2025. Separately, the board declared a quarterly cash dividend of $0.20 per share, payable July 3, 2025. These are routine annual-meeting matters, though the incentive plan drew 6,772,960 votes against.

Key points

  • Long-Term Incentive Plan approved: 22,019,458 for, 6,772,960 against, 25,103 abstain, 882,621 broker non-votes.
  • Advisory vote on named executive officer compensation passed: 27,902,248 for, 889,653 against.
  • PricewaterhouseCoopers LLP ratified as independent auditor for fiscal 2025: 27,675,330 for, 2,018,428 against.
  • Quarterly cash dividend of $0.20 per share declared May 19, 2025; payable July 3, 2025 to holders of record as of June 13, 2025.

The filing

CompanyCONMED (CNMD)
Form8-K, current report
Filed with the SECMay 21, 2025, 4:03 PM ET
Accession number0001174947-25-000828

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 21, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.